IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Li, X., Song, W., Shao, C., Shi, Y. & Han, W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell. Mol. Immunol. 16, 28–39 (2019).

    CAS  Article  Google Scholar 

  2. 2.

    Lantuejoul, S., Le Stang, N., Damiola, F., Scherpereel, A. & Galateau-Sallé, F. PD-L1 testing for immune checkpoint inhibitors in mesothelioma: for want of anything better? J. Thorac. Oncol. 12, 778–781 (2017).

    Article  Google Scholar 

  3. 3.

    Mimura, K. et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109, 43–53 (2018).

    CAS  Article  Google Scholar 

  4. 4.

    Kao, S. C. et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J. Thorac. Oncol. 12, 1421–1433 (2017).

    Article  Google Scholar 

  5. 5.

    Calabrò, L. et al. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? Cancer Immunol. Immunother. 64, 105–112 (2015).

    Article  Google Scholar 

  6. 6.

    Frigola, X. et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res. 17, 1915–1923 (2011).

    CAS  Article  Google Scholar 

  7. 7.

    Gong, B. et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J. Exp. Med. 216, 982–1000 (2019).

    CAS  Article  Google Scholar 

  8. 8.

    Khanna, S. et al. Malignant mesothelioma effusions are infiltrated by CD3+T cells highly expressing PD-L1 and the PD-L1+tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11, 1993–2005 (2016).

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Italian Ministry of Health (5x1000 funds 2014 and 2015; Ricerca Corrente 2017).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Maria Pia Pistillo.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pistillo, M.P., Carosio, R., Banelli, B. et al. IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade. Cell Mol Immunol 17, 410–411 (2020). https://doi.org/10.1038/s41423-019-0245-x

Download citation

Further reading

Search